# \[e-med\] Sources et prix des médicaments antituberculeux utlisés en cas de résistance (MSF-L'Union) **URL:** \ **Category:** e-med\ **Created:** [October 30, 2013, 10:28am UTC](https://talk.edrugplus.org/t/e-med-sources-et-prix-des-medicaments-antituberculeux-utlises-en-cas-de-resistance-msf-lunion/39698 "2013-10-30T10:28:31Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![c.bruneton](https://avatars.discourse-cdn.com/v4/letter/c/3ec8ea/32.png) [@c.bruneton](https://talk.edrugplus.org/u/c.bruneton)\ **Post date:** [October 30, 2013, 10:28am UTC](https://talk.edrugplus.org/t/e-med-sources-et-prix-des-medicaments-antituberculeux-utlises-en-cas-de-resistance-msf-lunion/39698/1 "2013-10-30T10:28:31Z")
(En anglais seulement.CB) DR-TB DRUGS UNDER THE MICROSCOPE SOURCES AND PRICES FOR DRUG-RESISTANT TUBERCULOSIS MEDICINES 3rd Edition ­ October 2013 MSF et The Union [http://www.msfaccess.org/sites/default/files/MSF\_TB\_Report\_UTM3rdEdition\_20](http://www.msfaccess.org/sites/default/files/MSF_TB_Report_UTM3rdEdition_20) 13.pdf Table of contents Background 2 DR-TB drugs under the microscope 4 Sources and prices of DR-TB medicines: sluggish progress 11 R&D: breakthrough drugs offer new hopes, but significant research gaps remain 15 What needs to happen 21 Methodology Drug Profiles Group two: Injectables 22 Amikacin 24 Kanamycin 26 Capreomycin Group Thre: Fluoroquinolones 28 Moxifloxacin 30 Levofloxacin 32 Ofloxacin Group Four: Oral bacteriostatic second-line agents 33 Ethionamide 34 Prothionamide 35 Cycloserine 37 Terizidone 38 PAS and PAS-sodium Group five: Agents with unclear eficacy 40 Clofazimine 42 Linezolid NEW DRUGS: 44 Bedaquiline Annexes 46 Annex 1: Summary table of all prices 48 Annex 2: Conditions of offer, as quoted by companies 49 Annex 3: Company contacts 50 References 54 Glossary 56 Abbreviations